Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure

Evaluation of the Effects on Peripheral and Central Haemodynamics Parameters, Safety, and Tolerance of Three-hour Intravenous Perfusion (0.1 mg/kg) of Ivabradine Given to Severe Congestive Heart Failure Patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00202579

Enrollment

Registered

2005-09-20

Start date

2004-09-30

Completion date

2006-02-28

Last updated

2024-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Congestive

Brief summary

To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure

Interventions

DRUGIvabradine

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* systolic congestive heart failure * sinus rhythm, HR \>= 80bpm

Exclusion criteria

* unstable cardiovascular condition

Design outcomes

Primary

Measure	Time frame
Twelve-lead ECG	—
Systolic and diastolic blood pressure	—
Haemodynamic parameters	—

Secondary

Measure	Time frame
Echocardiography	—
Neurohormones	—

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026